HR-3029-119
Received in the Senate and Read twice and referred to the Committee on Commerce, Science, and Transportation.
Sponsored by Andrea Salinas (D-OR)
What it does
This bill would direct the National Institute of Standards and Technology (NIST) to conduct measurement research and develop technical standards and best practices for screening synthetic nucleic acids (lab-made DNA and RNA) for biosecurity risks. It would also require NIST to convene a stakeholder consortium — including industry, universities, nonprofits, and customers — to develop consensus priorities and roadmaps for screening mechanisms. NIST would be required to submit a report to Congress within 18 months of the consortium's first meeting, and the bill would authorize $5 million per year for fiscal years 2027 through 2031 (totaling $25 million) for these activities.
Who benefits
Biosecurity researchers and public health agencies that would gain clearer, standardized screening tools. Legitimate synthetic biology companies that would benefit from a consistent national standard rather than a patchwork of requirements. Universities and nonprofit research institutions involved in the consortium process. Domestic biotechnology manufacturers who could use NIST-certified standards to demonstrate compliance. The general public, which could benefit from reduced risk of dangerous biological agents being synthesized through commercial DNA/RNA synthesis services.
Who is hurt
Synthetic nucleic acid synthesis companies that may face compliance costs in adapting to new standards, particularly smaller firms with fewer resources. Foreign competitors in the DNA synthesis market who may not be subject to the same standards, potentially shifting market share. Researchers who rely on rapid, low-friction access to synthetic nucleic acids and may face delays or additional screening steps. Taxpayers who would fund the $25 million authorization, though the per-year amount is modest.
Supporters argue
Supporters argue that commercial DNA and RNA synthesis services have become widely accessible, creating a potential pathway for bad actors to order genetic sequences that could be used to engineer dangerous pathogens. They contend that voluntary industry screening has been inconsistent and that NIST-developed technical standards — informed by a broad stakeholder consortium — would create a reliable, science-based baseline that protects national security without stifling legitimate research. The bill's $5 million annual authorization is modest relative to the biosecurity risk it addresses.
Opponents argue
Opponents argue that the bill authorizes standards development but lacks any enforcement mechanism, meaning companies could simply ignore the resulting best practices, leaving the biosecurity gap unaddressed. They contend that the consortium model, which includes industry as a key stakeholder, may produce standards that are too permissive to be effective, and that the 18-month reporting timeline and five-year authorization may not keep pace with the rapid advancement of AI-assisted biological design tools that could outrun any static screening framework.
Constitutional context
Congress has broad authority to fund scientific research and set technical standards through the Commerce Clause (Art. I, §8, cl. 3), and NIST's standard-setting role is well-established under that authority. No significant constitutional tension is present; the bill does not regulate private conduct directly, compel speech, or implicate digital surveillance in a way that would trigger Fourth or First Amendment scrutiny.
Checks and balances
The executive branch (NIST/Commerce Department) gains authority to develop and promote biosecurity standards; Congress retains oversight through the mandatory report to the Senate Commerce and House Science committees, and through the annual appropriations process that controls whether the authorized funds are actually spent.
Historical precedent
The Biden administration's 2023 Executive Order on AI and Biotechnology directed federal agencies to develop nucleic acid screening standards, and the Department of Homeland Security has issued voluntary screening guidelines for DNA synthesis providers, representing prior federal action in this space.